News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
399,094 Results
Type
Article (32120)
Company Profile (58)
Press Release (366916)
Multimedia
Podcasts (41)
Webinars (5)
Section
Business (112898)
Career Advice (1325)
Deals (24061)
Drug Delivery (94)
Drug Development (59752)
Employer Resources (104)
FDA (9974)
Job Trends (9095)
News (211702)
Policy (25545)
Tag
Academia (1843)
Accelerated approval (4)
Adcomms (20)
Allergies (71)
Alliances (42307)
ALS (63)
Alzheimer's disease (1114)
Antibody-drug conjugate (ADC) (107)
Approvals (9957)
Artificial intelligence (171)
Autoimmune disease (17)
Automation (7)
Bankruptcy (237)
Best Places to Work (7694)
BIOSECURE Act (16)
Biosimilars (84)
Biotechnology (42)
Bladder cancer (57)
Brain cancer (28)
Breast cancer (199)
Cancer (1702)
Cardiovascular disease (135)
Career advice (1116)
Career pathing (20)
CAR-T (111)
Cell therapy (309)
Cervical cancer (16)
Clinical research (48368)
Collaboration (709)
Company closure (1)
Compensation (464)
Complete response letters (19)
COVID-19 (2484)
CRISPR (32)
C-suite (123)
Cystic fibrosis (60)
Data (1655)
Decentralized trials (1)
Denatured (9)
Depression (38)
Diabetes (227)
Diagnostics (3580)
Digital health (10)
Diversity (4)
Diversity, equity & inclusion (33)
Drug discovery (88)
Drug pricing (100)
Drug shortages (28)
Duchenne muscular dystrophy (86)
Earnings (40744)
Editorial (39)
Employer branding (13)
Employer resources (94)
Events (46098)
Executive appointments (334)
FDA (10931)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (2)
Frontotemporal dementia (6)
Funding (496)
Gene editing (77)
Generative AI (13)
Gene therapy (244)
GLP-1 (704)
Government (4117)
Grass and pollen (5)
Guidances (117)
Healthcare (11417)
Huntington's disease (20)
IgA nephropathy (24)
Immunology and inflammation (94)
Indications (24)
Infectious disease (2628)
Inflammatory bowel disease (85)
Inflation Reduction Act (7)
Influenza (54)
Intellectual property (75)
Interviews (232)
IPO (10460)
IRA (40)
Job creations (1752)
Job search strategy (956)
Kidney cancer (7)
Labor market (22)
Layoffs (288)
Leadership (10)
Legal (7061)
Liver cancer (54)
Lung cancer (243)
Lymphoma (115)
Machine learning (8)
Management (32)
Manufacturing (241)
MASH (63)
Medical device (5935)
Medtech (5936)
Mergers & acquisitions (14039)
Metabolic disorders (620)
Multiple sclerosis (55)
NASH (20)
Neurodegenerative disease (76)
Neuropsychiatric disorders (25)
Neuroscience (1526)
NextGen: Class of 2025 (3657)
Non-profit (2772)
Now hiring (6)
Obesity (346)
Opinion (195)
Ovarian cancer (55)
Pain (57)
Pancreatic cancer (72)
Parkinson's disease (118)
Partnered (13)
Patents (171)
Patient recruitment (64)
Peanut (38)
People (24958)
Pharmaceutical (18)
Pharmacy benefit managers (11)
Phase I (14620)
Phase II (21022)
Phase III (17032)
Pipeline (1059)
Policy (140)
Postmarket research (1846)
Preclinical (6084)
Press Release (28)
Prostate cancer (83)
Psychedelics (28)
Radiopharmaceuticals (206)
Rare diseases (277)
Real estate (2583)
Recruiting (44)
Regulatory (16212)
Reports (23)
Research institute (1592)
Resumes & cover letters (195)
Rett syndrome (4)
RNA editing (3)
RSV (47)
Schizophrenia (64)
Series A (80)
Series B (45)
Service/supplier (4)
Sickle cell disease (38)
Special edition (6)
Spinal muscular atrophy (137)
Sponsored (19)
Startups (1890)
State (1)
Stomach cancer (11)
Supply chain (55)
Tariffs (37)
The Weekly (31)
Vaccines (726)
Venture capitalists (29)
Weight loss (252)
Women's health (13)
Worklife (10)
Date
Today (121)
Last 7 days (621)
Last 30 days (1930)
Last 365 days (20856)
2025 (7512)
2024 (22361)
2023 (25260)
2022 (33390)
2021 (35894)
2020 (34072)
2019 (27913)
2018 (21257)
2017 (20208)
2016 (18705)
2015 (21497)
2014 (15954)
2013 (12877)
2012 (13625)
2011 (14402)
2010 (13079)
Location
Africa (570)
Alabama (31)
Alaska (3)
Arizona (91)
Arkansas (5)
Asia (25995)
Australia (4685)
California (3826)
Canada (1267)
China (381)
Colorado (159)
Connecticut (165)
Delaware (112)
Europe (62432)
Florida (582)
Georgia (132)
Hawaii (1)
Idaho (28)
Illinois (298)
India (23)
Indiana (198)
Iowa (8)
Japan (130)
Kansas (64)
Kentucky (16)
Louisiana (10)
Maine (28)
Maryland (669)
Massachusetts (2746)
Michigan (106)
Minnesota (146)
Mississippi (1)
Missouri (50)
Montana (20)
Nebraska (10)
Nevada (40)
New Hampshire (21)
New Jersey (1202)
New Mexico (15)
New York (1145)
North Carolina (526)
North Dakota (5)
Northern California (1760)
Ohio (118)
Oklahoma (6)
Oregon (10)
Pennsylvania (835)
Puerto Rico (6)
Rhode Island (13)
South America (798)
South Carolina (13)
South Dakota (1)
Southern California (1435)
Tennessee (52)
Texas (473)
United States (14104)
Utah (88)
Virginia (99)
Washington D.C. (38)
Washington State (312)
West Virginia (2)
Wisconsin (31)
399,094 Results for "morphosys ag".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Ad hoc: Novartis BidCo Germany AG Intends to Implement a Merger Squeeze-out of MorphoSys AG’s Minority Shareholders
MorphoSys AG announces that Novartis BidCo Germany AG informed the MorphoSys AG Management Board of its intention to merge MorphoSys AG as transferring company into Novartis BidCo Germany AG.
June 20, 2024
·
4 min read
Deals
MorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys’ Minority Shareholders
MorphoSys AG announced that the company has entered into a delisting agreement with Novartis BidCo AG and Novartis AG following the successful closing of the acquisition of MorphoSys by Novartis in May 2024.
June 20, 2024
·
10 min read
Business
MorphoSys AG Reports First Quarter 2024 Financial Results
MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the first quarter of 2024.
April 29, 2024
·
18 min read
Layoffs
Novartis Cuts MorphoSys Sites in Boston, Munich, Affecting 330 Jobs
The closures follow Novartis’s acquisition of MorphoSys earlier this year.
December 19, 2024
·
1 min read
·
Annalee Armstrong
Business
MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the fourth quarter and the full year 2023.
March 13, 2024
·
22 min read
Business
MorphoSys AG Reports First Nine Months and Third Quarter 2023 Financial Results
MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the third quarter and the first nine months of 2023.
November 15, 2023
·
15 min read
Business
MorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis
The Management Board and Supervisory Board of MorphoSys AG issued a joint reasoned statement on the voluntary public takeover offer by Novartis BidCo AG, a wholly owned indirect subsidiary of Novartis AG, recommending that shareholders accept the offer and tender their MorphoSys shares.
April 11, 2024
·
9 min read
Deals
MorphoSys Enters into Business Combination Agreement to be Acquired by Novartis for € 2.7 Billion Equity Value
MorphoSys AG announced the company entered into a Business Combination Agreement with Novartis data42 AG and Novartis AG based on Novartis’ intention to submit a voluntary public takeover offer for all outstanding MorphoSys no-par value bearer shares at an offer price of € 68.00 per share in cash.
February 5, 2024
·
16 min read
Deals
MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR Act
MorphoSys AG announced the receipt of U.S. antitrust clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in connection with the proposed acquisition of MorphoSys by Novartis AG, following the expiration of the HSR Act waiting period.
March 22, 2024
·
8 min read
Business
MorphoSys AG Reports Second Quarter and First Half 2023 Financial Results
MorphoSys AG reports results for the second quarter and first half year of 2023.
August 9, 2023
·
14 min read
1 of 39,910
Next
